Dongkook Pharmaceutical Reports Q3 Sales of 159.7 Billion KRW, Up 10.1% YoY with Balanced Growth Across All Sectors

[Asia Economy Reporter Lee Gwan-joo] Dongkook Pharmaceutical announced on the 14th that its consolidated sales for the third quarter of this year reached 159.7 billion KRW, a 10.1% increase compared to the same period last year. Operating profit rose by 2.8% to 11.9 billion KRW.

Cumulative sales up to the third quarter amounted to 495.2 billion KRW, and operating profit was 55.2 billion KRW, representing increases of 11.6% and 17.7%, respectively, compared to the same period last year.

By business division, all sectors including the OTC (Over-The-Counter) division, Overseas division, ETC (Ethical Therapeutic Drugs) division, Healthcare division, and Dongkook Life Science (subsidiary) showed balanced growth.

In the OTC sector, sales grew year-on-year due to increased demand for wound treatment product Madecassol, venous circulation enhancer Sensia, and gum medicine Insadol (Plus). Additionally, the newly launched prostate enlargement urinary disorder treatment Karitopoten, as a new growth driver, is receiving positive market responses and is expected to continue its growth trend in the fourth quarter.

The export (Overseas division) sector nearly achieved 100% of its sales target. Both raw materials and finished products of the glycopeptide-class antibiotic Teicoplanin showed steady growth.

In the ETC division, chronic disease-related internal medicine drugs such as the hyperlipidemia combination drugs 'Rosutanjet,' 'Pitaron-F,' and 'Atobanduo' led growth, and related drugs centered on 'Masibone S Solution,' the first domestic liquid osteoporosis treatment, are rapidly expanding. The oral diabetes treatment (DPP-4 Inhibitor drug) launched last month has been well received, and the product lineup in the diabetes field is expected to gradually strengthen.

In the healthcare division, balanced growth has been achieved across all businesses including lifestyle health and online, centered on the beauty business (cosmetics). In particular, the 'Centellian24' brand surpassed cumulative sales of 600 billion KRW.

The subsidiary Dongkook Life Science is showing growth and solid sales of its main contrast agent products such as Pamiray, Uniray, and Duoray, and based on this, plans to create new demand through business diversification in medical devices including ultrasound, mobile CT, artificial intelligence (AI), and in vitro diagnostic devices.

This content was produced with the assistance of AI translation services.